Journal of Clinical Oncology
Articles in this Issue
Performance of a novel polymeric FdUMP (CF10) versus 5-FU in efficacy and tolerability in preclinical models of colorectal cancer.
185 Background: Fluoropyrimidines remain the cornerstone of systemic therapy for metastatic colorectal cancer (mCRC), but...
Early detection of hepatocellular carcinoma using red blood cell DNA signatures.
601 Background: Liver cancer is the third leading cause of cancer-related mortality worldwide, with hepatocellular carcino...
A clinical and molecular comparative analysis of KRAS exon-2 and KRAS non-exon-2 mutated colorectal cancer.
212 Background: KRAS-mutated colorectal cancer (CRC) represents a biologically heterogeneous group of diseases. Majority o...
Comparison of anti-PD-L1 therapy in advanced hepatocellular carcinoma with or without metabolic syndrome: A multi-center, retrospective, and propensity score-matched study.
537 Background: Hepatitis-associated hepatocellular carcinoma (HCC) exhibits clinical benefits from immune checkpoint inhi...
Impact of metastatic sites and Lauren subtype on survival outcomes of first-line PD-1 inhibitors combined with chemotherapy in HER2-negative advanced gastric cancer: A meta-analysis.
393 Background: Multiple landmark phase III clinical trials demonstrated overall survival (OS) benefit when using PD-1 blo...
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in malignant peritoneal mesothelioma (MPM).
816 Background: MPM is a rare malignancy, with roughly 300 new cases in the United States annually. CRS-HIPEC has evolved...
Real-world (rw) outcomes of durvalumab plus gemcitabine and cisplatin (D + GemCis) or GemCis in patients (pts) with advanced biliary tract cancer in the US.
497 Background: D + GemCis is approved for the treatment of locally advanced or metastatic biliary tract cancer (aBTC) bas...
Trends in locoregional colorectal cancer incidence by race and ethnicity in US adults aged 45-49 with updated screening guidelines (2013-2022).
44 Background: Colorectal cancer (CRC) screening guidelines from the American Cancer Society recommended lowering the star...
Efficacy data of oxaliplatin retreatment in patients with metastatic colorectal cancer in a real-world setting.
167 Background: Retreatment with oxaliplatin-based regimens after progression to standard therapy, is a common practice in...
Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405.
198 Background: The Hedgehog (Hh) signaling pathway regulates tissue patterning, growth and differentiation, including wit...
Optimizing nutrition in patients with pancreatic cancer (NUANCE study).
696 Background: Patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) experience significantly worse outcom...
Development of a prognostic nomogram to guide clinical decision-making in metastatic gastric cancer: A Latin American cohort study.
325 Background: Metastatic gastric cancer (mGC) is associated with dismal outcomes, and most patients eventually receive o...
Oxaliplatin-induced portal hypertension in colorectal cancer: A systematic review of incidence, mechanisms, and predictive markers.
117 Background: Oxaliplatin remains a cornerstone of colorectal cancer (CRC) chemotherapy but is frequently complicated by...
Survival outcomes for phase II study of durvalumab (D) and tremelimumab (T) plus PET-directed chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma (EA).
397 Background: We previously found that adding D to induction FOLFOX and PET-directed CRT in resectable EA was safe and h...
Brain metastases in gastro-esophageal cancers: Survival and prognostic insights from an Asian cohort.
323 Background: Brain metastases (BrM) from gastro-esophageal cancers are rare and often associated with poor prognosis. A...
Outcomes of rare histologic variants of esophageal cancer: A National Cancer Database analysis.
299 Background: Esophageal cancer is most often adenocarcinoma or squamous cell carcinoma, while rare histologies such as...
Phase III randomized controlled trial to confirm efficacy of surgery plus postoperative dose-modified S-1 adjuvant chemotherapy against surgery alone for vulnerable elderly patients with pathological stage II/III gastric cancer: JCOG1507 (BIRDIE trial).
347 Background: In Japan, the standard treatment for resectable gastric cancer is primary gastrectomy followed by adjuvant...
Utility of pancreatic cancer screening and detection in patients with pathogenic germline variants.
690 Background: Most patients with pancreatic cancer (PC) present with late-stage (unresectable or metastatic) disease. Ce...
Second-line irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study.
148 Background: After failure of first-line oxaliplatin (LOHP)/5-FU for metastatic colorectal cancer (mCRC), irinotecan (C...
Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study.
434 Background: In the phase 3 DESTINY-Gastric04 study (NCT04704934), T-DXd significantly improved overall survival versus...
Sociodemographic disparities in the place of death in patients with colorectal cancer: Analysis of real-world CDC WONDER data.
46 Background: Most patients with advanced colorectal cancer (CRC) prefer death at home or in hospice, but Place of Death...
Do glucagon-like peptide 1 receptor agonists offer protective effect on colon cancer risk?
91 Background: Previous evidence have evaluated the impact of GLP-1 receptor agonists (GLP-1 RA) on colon cancer risk in p...
Disparities in stage III–IV squamous cell anal carcinoma (SCAC): Real-world treatment patterns, outcomes, and implications for immunotherapy.
6 Background: SCAC is a rare malignancy with rising incidence and few therapeutic advances. Prior studies have shown that...
Cracking the code: Clinical predictors of brain metastases in colorectal cancer.
241 Background: Despite occurring in only 1-3% of metastatic colorectal cancer (mCRC) patients, brain metastases predict a...
Associations of 9p21 deletions on chemotherapy outcomes in pancreatic ductal adenocarcinoma.
783 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States, w...